Abstract
Pulmonary hypertension related to chronic lung disease, mainly represented by COPD and idiopathic pulmonary fibrosis, is associated with a worse outcome when compared with patients only affected by parenchymal lung disease. At present, no therapies are available to reverse or slow down the pathological process of this condition and most of the clinical trials conducted to date have had no clinically significant impact. Nevertheless, the importance of chronic lung diseases is always more widely recognised and, along with its increasing incidence, associated pulmonary hypertension is also expected to be growing in frequency and as a health burden worldwide. Therefore, it is desirable to develop useful and reliable tools to obtain an early diagnosis and to monitor and follow-up this condition, while new insights in the therapeutic approach are explored.
Abstract
New prospective in the management of pulmonary hypertension related to chronic lung diseases http://bit.ly/2lW4CfE
Footnotes
Provenance: Publication of this peer-reviewed article was sponsored by Boehringer Ingelheim, Germany (principal sponsor European Respiratory Review issue 153).
Conflict of interest: D. Elia has nothing to disclose.
Conflict of interest: A. Caminati reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: M. Zompatori has nothing to disclose.
Conflict of interest: R Cassandro has nothing to disclose.
Conflict of interest: C. Lonati has nothing to disclose.
Conflict of interest: F. Luisi has nothing to disclose.
Conflict of interest: G. Pelosi has nothing to disclose.
Conflict of interest: S. Provencher reports grants and personal fees from Actelion Pharmaceuticals, and grants from Boehringer Ingelheim and Resverlogix Corp, outside the submitted work.
Conflict of interest: S. Harari reports grants and personal fees from Roche, Actelion and Boehringer Ingelheim, outside the submitted work.
- Received June 9, 2019.
- Accepted September 22, 2019.
- Copyright ©ERS 2019.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.